JPRN-UMIN000002314已完成3 期
Randomized phase III trial of erlotinib versus docetaxel for patients with previously treated advanced non-small cell lung cancer - Docetaxel and Erlotinib Lung cancer trial (DELTA)
ational Hospital Organization Headquarters Center for Support and Education of Clinical Research0 个研究点目标入组 300 人开始时间: 2009年8月11日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of obvious distributed interstitial pneumonia or pulmonary fibrosis detected by chest CT (Patients with radiation peumonitis limited to radiation field are eligible) 2)History of obvious drug induced interstitial pneumonia or pneumoconiosis 3)History of symptomatic brain metastases. Patients with brain metastases are eligible, if thier brain metastases are controlled by radiotherapy or drug therapy. 5)History of severe drug allergy 6)History of poorly controlled pleural effusion, pericardial effusion or ascites necessitating drainage 7)History of active infection or other serious disease condition (poorly controlled diabetes mellitus, poorly controlled cardiac disease, GI bleeding, cirrhosis, ileus, persistant watery diarrhea, etc) 8)History of active double cancer 9)History of active psychological disease. 10) History of pregnancy or lactation 11) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-GBETOP (European Thoracic Oncology Platform)500
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-IEETOP (European Thoracic Oncology Platform)500
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-DEETOP (European Thoracic Oncology Platform)80
进行中（未招募）
不适用
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-NLETOP (European Thoracic Oncology Platform)500
进行中（未招募）
不适用
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.EUCTR2012-001896-35-ATETOP (European Thoracic Oncology Platform)500